Literature DB >> 110487

Uptake and distribution of daunorubicin and daunorubicin-DNA complex in mice as studied by whole-body autoradiography and liquid chromatography.

B Andersson, M Beran, B Eberhardsson, S Eksborg, P Slanina.   

Abstract

The tissue distribution of daunorubicin (D) and daunorubicin-DNA complex (D-DNA) was studied in mice by means of whole-body autoradiography (WBA) and high-performance liquid chromatography (HPLC). A higher accumulation of radioactivity in the blood after 1 min and a lower initial accumulation in the cardiac muscle were found after administration of 3H-D-DNA than after the infection of free drug. Comparative studies of plasma levels of daunorubicin and daunorubicinol (DOH) in D- and D-DNA-treated animals by HPLC showed that the initial differences were negligible from 2 h onward. A rapid accumulation of D in bone marrow occurred in both D- and D-DNA-treated mice. D reached its maximum level after 1 h and was almost constant for 12 h. A new WBA finding was a rapid and specific accumulation of radioactivity in the pituitary gland, in the thyroid, and in the pancreatic islets, which might be of some interest in consideration of possible late endocrine side effects of anthraquinone glycoside therapy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 110487     DOI: 10.1007/bf00258289

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  19 in total

1.  Accumulation and retention of mercury in the mouse. I. An autoradiographic study after a single intravenous injection of mercuric chloride.

Authors:  M BERLIN; S ULLBERG
Journal:  Arch Environ Health       Date:  1963-05

2.  Studies on the distribution and fate of S35-labelled benzylpenicillin in the body.

Authors:  S ULLBERG
Journal:  Acta Radiol Suppl       Date:  1954

3.  Adriamycin (NSC-123127) and its analogs.

Authors:  D W Henry
Journal:  Cancer Chemother Rep 2       Date:  1974-12

4.  Decreased cardiac toxicity of adriamycin and daunorubicin when bound to DNA.

Authors:  A Langslet; I Oye; S O Lie
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-11

5.  Daunorubicin-DNA: further clinical trials in acute non-lymphoblastic leukemia.

Authors:  G Cornu; J L Michaux; G Sokal; A Trouet
Journal:  Eur J Cancer       Date:  1974-11       Impact factor: 9.162

6.  Biologic activity of some adriamycin (NSC-123127) derivatives.

Authors:  L Lenaz; A Necco; T Dasdia; A Di Marco
Journal:  Cancer Chemother Rep       Date:  1974 Nov-Dec

7.  Distribution of tritiated daunomycin (NSC-82151) in normal rats.

Authors:  A Rusconi; G Di Fronzo; A Di Marco
Journal:  Cancer Chemother Rep       Date:  1968-04

8.  Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods.

Authors:  N R Bachur; A L Moore; J G Bernstein; A Liu
Journal:  Cancer Chemother Rep       Date:  1970-04

9.  Liquid chromatographic determination of daunorubicin and daunorubicinol in plasma from leukemic patients.

Authors:  S Eksborg; H Ehrsson; B Andersson; M Beran
Journal:  J Chromatogr       Date:  1978-06-01

10.  Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity.

Authors:  A J Weiss; G E Metter; W S Fletcher; W L Wilson; T B Grage; G Ramirez
Journal:  Cancer Treat Rep       Date:  1976-07
View more
  3 in total

Review 1.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

2.  Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients.

Authors:  S O Nilsson; B Andersson; S Eksborg; M Beran; H Ehrsson
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

3.  Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex.

Authors:  B Andersson; M Beran
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.